GnRH agonist instead of hCG to trigger ovulation in GnRH antagonist cycles Dec 10, 2004.

Slides:



Advertisements
Similar presentations
Ovulation Induction Dr Elsamawal El Hakim
Advertisements

The Diagnosis and Treatment of Infertility
Ovulation induction TAQI Consultant OB/GYN,Infertility,IVF
Benefits and Risks of GnRH/LHRH Agonists and Antagonists in Advanced Prostate Cancer Patients John Trachtenberg, MD Director, Prostate Cancer Princess.
ALTERNATE DAY TRIPTORELIN: A COST EFFECTIVE METHOD FOR CONTROLLED OVARIAN HYPERSTIMULATION E. Karatekeli, H. Özörnek, E. Ergin, B. Ongun EUROFERTIL REPRODUCTIVE.
Dr. Hakan ÖZÖRNEK EUROFERTIL Reproductive Health Center
Jeopardy Q 1 Q 6 Q 11 Q 16 Q 21 Q 2 Q 7 Q 12 Q 17 Q 22 Q 3 Q 8 Q 13
What is a systematic review a review strives to comprehensively identify and track down all the literature on a given topic incorporates a specific.
Ovarian Stimulation in IUI- Overview
The use of hCG in microdose to support ovarian folliculgenesis Michel Abou Abdallah, M.D.
Luteal Phase Support in ART Cycles
 OHSS is a serious, potentially life- threatening, iatrogenic complication of “controlled” ovarian stimulation.  To optimize the ovarian response without.
Shahar Kol, Maccabi Health Care Services Rambam Health Care Campus Technion, Israel Institute of Technology.
ART-IVF: the Long and Short of it Professor Ernest Hung Yu NG Department of Obstetrics & Gynaecology The University of Hong Kong.
Elonva in poor responders
Prevention of OHSS Shahar Kol, IVF Unit Rambam Health Care Campus, and Macabbi Health Services, Haifa, Israel. February 2012.
Minimal Monitoring of Ovulation Induction (OI) Is It Safe? Mustafa Uğur Zekai Tahir Burak Women’s Health Education and Research Hospital, Ankara, Turkey.
OHSS PREVENTION: YES, WE CAN! Shahar Kol, IVF Unit Rambam Health Care Campus, and Faculty of Medicine, Technion, Israel Institute of Technology, February,
Does GnRHa triggering completely abolish OHSS? Dec 3 rd, 2010.
Critical analysis of OC use in ovulation induction Prof.Dr.Erkan Alataş Pamukkale University Faculty of Medicine Department of Obstetrics and Gynecology.
RECOMBINANT LH, RECOMBINANT HCG AND GNRH AGONIST TO TRIGGER OVULATION IN ANTAGONIST CYCLES: A CRITICAL EVALUATION SHAHAR KOL AUGUST 2014.
Role of Anti-Mullerian hormone in prediction of Assisted Reproductive Technology outcomes Leili Safdarian M.D. Khadigeh Khosravi M.D. Marzieh Agha Hosseini.
IVM is ready as a treatment for PCOS patients
Discontinuation of rLH two days before hCG may increase the number of oocytes retrieved in IVF Jessica B Spencer 1*, Aimee S Browne 1, Susannah D Copland.
LUTEAL PHASE SUPPORT An evidence-based approach M. Aboulghar Cairo – Egypt IZMIR 2008.
ART Assisted reproductive technology Dithawut Khrutmuang MD.
Planning of GnRH antagonist cycles
The optimal choice of gonadotrophin in GnRH antagonist protocols Prof Dr P Devroey.
Levent M. SENTURK, M.D., Professor in Ob&Gyn Istanbul University Cerrahpasa School of Medicine Dept. of Ob&Gyn, Division of Reproductive Endocrinology,
Dr. Milton Leong Director
The Effect of Bromocriptine-Rebound Method on Ongoing Pregnancy and Live Birth after Intracytoplasmic Sperm Injection Cycles: a Randomized Clinical Trial.
GNRH-A TRIGGER AND INDIVIDUALIZED LUTEAL PHASE HCG SUPPORT WILL AVOID OHSS IN PCOS PATIENTS. Shahar Kol, IVF Unit Rambam Health Care Campus, and Faculty.
Agonist vs Antagonist Dr. Milton Leong.
How to schedule GnRH antagonist cycles?
Recommended Dosage of GnRH Antagonist is Too High Presented by Dr. Milton Leong, MD DSc(McGill) Director, IVF Centre.
ART FOR PCOS-DIFFICULTIES AND SOLUTIONS Dr. Bulent Urman American Hospital, ISTANBUL Assisted Reproduction Unit Koç University, Faculty of Medicine Department.
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
Luteal coasting post GnRH agonist trigger
Georg Griesinger UK-SH, Campus Luebeck Germany. We have a problem…
Female Reproductive Cycle
(Miz Medi Hospital) Jung-Hyun Cho, M.D. (Miz Medi Hospital) Minimal Ovarian Stimulation.
Role of decreased androgens in the ovarian response to stimulation in older women Fertil Steril Jan;99(1):5-11 Presented by Hsing-Chun Tsai
Patient scheduling & Luteal phase support Konstantin Y. Boyarsky MD, PhD IVF Clinics “GENESIS” Department of Obstetrics and Gynecology, State Pediatric.
An analysis of 2,566 cycles Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: An analysis of 2,566.
The Endometrium and Frozen Embryo Transfer
ART’de Aşırı Cevabın Yönetimi
Schematic diagram of idealized regimens using exogenous gonadotropins for fertility induction. A. Step-up regimen for ovulation induction. After menses,
The timeline shows the day of menstrual cycle for a typical patient
How IVF Protocols Work to Enhance the Success of IVF: Agonist vs Antagonist Dr Dimitrios Dovas MD Newlife IVF Greece.
Drug protocols for ovulation induction. A
Drug protocols for ovulation induction. A
Isfahan University of Medical Sciences Dissertation defense meeting Resident of Gynecology and Obstetrics.
Use of GnRH antagonists for IVF
Prevention of ovarian hyperstimulation syndrome in OHSS patients
The approach to the PCOS patient undergoing IVF
به نام خدا Ovarian hyperstimulation syndrome
Hormonal profile of the same oocyte donors stimulated with either GnRH antagonist or agonist compared with natural cycles.
Drug protocols for ovulation induction. A
The effect of the duration of stimulation on ART outcomes
Antagonists in poor-responder patients
Reducing implantation failure: novel approach to luteal phase support
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Ovarian stimulation protocols for IVF: is more better than less?
Luteal Phase Management
How to do a study? Prof. P. Devroey.
Shahar Kol, IVF Unit, Elisha Hospital, Haifa, Israel
novel approach to luteal phase support
Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection.
Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.
First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for.
Presentation transcript:

GnRH agonist instead of hCG to trigger ovulation in GnRH antagonist cycles Dec 10, 2004

Quick overview Does that trigger work? Yes (evidence). Is endogenous LH surge physiological? Not exactly (evidence). Effect on the luteal phase? Complete luteolysis (evidence). Clinical use? In the context of OHSS prevention (evidence/opinion). Future? Establish use in OHSS prevention (RCT), fine-tune trigger for other uses?

Triggering of ovulation by a GnRH agonist in patients pretreated with a GnRH antagonist Pilot study, Ovulation induction 5 patients. LH and FSH rise in all 5 patients. Olivennes et al, Fertil Steril 66:151, 1996

Itskovitz-Eldor et al, Hum Reprod 15:1965, 2000 Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction with special reference to the prevention of OHSS: preliminary report Itskovitz-Eldor et al, Hum Reprod 15:1965, 2000

Materials and Methods 8 Women considered at risk of developing OHSS: >20 follicles >11mm and/or E2 levels>3000ng/ml on the last stimulation day. Ovarian stimulation with rFSH (150IU or 225 IU daily) and ganirelix 0.25mg daily from day 6. Induction of LH surge with a single injection of triptorelin 0.2mg SC ~30hr after the last injection of ganirelix. Luteal support: E2+P

Results Mean no. of follicles>11mm=25.1±4.5 Median E2 (pg/ml)=3675 (range 2980–7670) Mean number of oocytes=23.4 (±15.4), 83% MII Mean number of embryos=15.4±6.6 7 ETs from fresh embryos: 1 pregnancy 17 ETs from frozen-thawed embryos: 4 pregnancies

Median values of serum LH and E2 after injection of triptorelin 0.2mg Time after injection (n=8) Serum LH (IU/l) Serum estradiol (pg/ml) Pre-dose 2.4 4775 0.5 h 12.7 4630 1 h 14.3 4505 2 h 73.7 5080 4 h 219 5540 10-12 h 71.0 6000 Day of OPU 7.9 2375 Day of ET 0.8 963 First week post-ET 1.0 145 Itskovitz et al, 2000

Normal LH surge Hoff et al, 1983

High responders Itskovitz et al, 1991

Agonist-triggered LH surge vs. natural surge Maximal LH at 4 h vs. 14h Surge duration 24 h vs. 48 h Surge amplitude – comparable.

Summary The ability of a single bolus of triptorelin 0.2mg to trigger an adequate LH surge in stimulation cycles using a GnRH antagonist protocol was demonstrated. The results suggest that this regimen may prove highly effective in terms of OHSS prevention, though further studies are needed to establish this potential advantage.

Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization Fauser BC, et al J Clin Endoc Metab 87:709, 2002

(Randomized multicenter study) Protocol (Randomized multicenter study) 10000IU 0.2 mg 0.5 mg Fauser et al, 2002

Clinical outcome (mean±SD) Triptorelin (n=17) Leuprorelin (n=15) hCG (n=15) Number of oocytes/subject 9.8 ± 5.4 8.7 ± 4.5 8.3 ± 3.3 Proportion of metaphase II oocyte 72 ± 18% 85 ± 17% 86 ± 17% Fertilization rate 61 ± 30% 62 ± 23% 56 ± 18% No. of embryos obtained per subject, grades 1 and 2 pooled 2.7 ± 3.4 3.2 ± 2.6 3.3 ± 2.0 Implantation rate 15 ± 34% 18 ± 37% 7 ± 14% Ongoing pregnancy rate 18% 20% 13% Fauser et al, 2002

Serum hormone concentrations (AUC) during triggering of final oocyte maturation Triptorelin (n=15) Leuprorelin (n=15) hCG (n=15) LH(0–24h) (IU/L)1 59 ± 142 53 ± 142 2.7 ± 2.2 FSH(0–24h) (IU/L)1 14.5 ± 3.82 14.3 ± 3.72 5.0 ± 1.2 E2(0–2 wk) (pg/ml)1 252 ± 1542 196 ± 1113 515 ± 286 P(0–2 wk) (ng/ml)1 12.5 ± 7.72 15.2 ± 7.12 37.8± 17.1 1 PANCOVA < 0.001 comparing all three groups. 2 P = 0.0001 vs. hCG group (paired t test). 3 P = 0.0006 vs. hCG group (paired t test). Fauser et al, 2002

Serum concentrations of LH (hCG), FSH, E2 and P Fauser et al, 2002

Summary (abstract) “Corpus luteum formation is induced by GnRH agonists with luteal phase steroid levels closer to the physiological range compared with hCG”. “This more physiological approach for inducing oocyte maturation may represent a successful and safer alternative for IVF patients”. But…

Normal menstrual cycle Yen and Jaffe 1991

hCG (8 oocytes) 1800 Agonists (9 oocytes)

Beckers GM et al, J Clin Endoc Metab Nonsupplemented luteal phase characteristics after the administration of r-hCG, r-LH, or GnRH-agonist to induce final oocyte maturation in IVF patients after ovarian stimulation with r-FSH and GnRH antagonist Beckers GM et al, J Clin Endoc Metab 88:4186, 2003

Study protocol 40 Women Randomized two-center study Ovarian stimulation: r-FSH (150 IU/d, fixed) combined with GnRH antagonist (antide 1 mg/d). No luteal support. Induction of oocyte maturation by: r-hCG (Ovidrel, 250 g) r-LH (Luveris, 1 mg) GnRH agonist (triptorelin, 0.2 mg) Beckers et al, 2003

Results Median duration of the luteal phase: r-hCG-13d, r-LH-10d, GnRHa–9d (P<0.005) Serum LH day of OPU (IU/l): r-hCG-1.3, r-LH-50.6, GnRHa-5.5 (P<0.001) Median AUC per day for LH: r-hCG-0.50, r-LH-2.35, GnRHa-1.07 (P<0.001) Median AUC per day for Progesterone: r-hCG-269, r-LH-41, GnRHa-16 (P<0.001) Low pregnancy rate (overall 7.5%) Beckers et al, 2003

Summary Luteal phase is insufficient after ovarian stimulation for IVF in combination with daily GnRH antagonist in all three groups. Luteal support is mandatory after ovarian stimulation with GnRH antagonist. Beckers et al, 2003

However… There is a difference between the groups: luteal E2 and P levels in the agonist group are practically zero!

Based on the last 2 papers: following GnRH-a trigger biosynthesis of sex steroids by the CL is practically zero. Physiological range? Luteolysis?

Nevo et al, Fertil Steril 79:1123, 2003 Lower levels of inhibin A and pro-alpha C during the luteal phase after triggering oocyte maturation with GnRH agonist versus hCG Nevo et al, Fertil Steril 79:1123, 2003

Clinical characteristics Nevo et al, 2003

Luteal phase Natural cycle day 7-9= 75 pg/ml vs. 18 Nevo et al, 2003

Summary GnRH antagonist-based protocol for ovulation induction enables the use of a GnRH-a trigger. The lower levels of steroidal and nonsteroidal hormones, which are secreted by the corpora lutea, reflect luteolysis, and may explain the mechanism of OHSS prevention by GnRH-a. Pregnancy post agonist trigger does not rescue the CL!!! Nevo et al, 2003

Luteolysis post agonist: an old concept Casper and Yen, Science, 1979, 205:408 5 volunteers , mid-luteal agonist Luteolysis occurred as indicated by parallel fall in E2 and P4. Suggested as “morning after” injection to prevent pregnancy.

Suggested mechanism of luteolysis Aberrant LH surge sufficient for final oocyte maturation but insufficient for complete CL formation. Repeated agonist dose does so not prolong surge. Aberrant luteal LH secretion. Agonist given 6 days later – no LH response (emperaire 1994).

Pregnancy rate (normal responder) Segal FS, 1992: GnRH-a 20%, hCG 19% Gonen JCEM, 1990: GnRH-a 3/9, hCG 0/9 Lanzone FS, 1994: similar rate. Fauser JCEM 2002: agonist 18%-20%, hCG 13%

ESHRE 2004 Ossina et al: Triggering ovulation in GnRH antagonist protocol: triptorelin 0.1 mg vs. hCG, randomized multicenter trial. 101 patients, luteal support? Pregnancy: 48% vs. 42% Westergaard et al: Significant reduction of clinical pregnancy by use of GnRH agonist compared to hCG to induce ovulation in FSH/GnRH antagonist cycles. 96 patients, luteal support: Crinone, 4 mg estradiol. Pregnancy: hCG=39%, agonist =7.5%

ESHRE 2004 (contd) Triggering ovulation with leuprolide acetate (LA) is associated with lower pregnancy rates (Bankowski et al, Johns Hopkins) May 2000 – July 2003: antagonist cycles, trigger hCG 10,000 routinely, if E2>3000pg/ml: trigger with 1 mg LA. hCG: 317 patients, LA: 97 patients Peak E2: 2050 vs. 4800. Oocytes: 10 vs. 21, embryos: 5.6 vs. 12.5 Pregnancy: 21.5% vs. 11.3% Three cases of severe OHSS all in the hCG group…

ESHRE 2004 (contd) GnRH agonist as a novel luteal support. Loumaye et al . 24 IUI patients. Ovulation triggered with buserelin 0.2 mg. Luteal support with 0.1 mg daily. Normal luteal phase. Importance of dose, type of agonist.

The question of pregnancy rate (normal responder) The importance of adequate luteal support. As with egg donation patients.

The question of pregnancy rate (high responder) Pellicer FS 1996: Lower implantation rates in high responders: 0% vs. 18.5%. Simon HR 1995: 16.3 vs. 33.3% Simon FS 1998: Increasing uterine receptivity by decreasing estradiol levels…with step-down regimen. Thin rope: 17% cancellation..

Clinical experience, 40 cycles Rambam Medical Center Max E2=21,436 pmol/l, 23 oocytes, 11 embryos. Fresh ET: 13% pregnancy rate Thaw cycles: 23% pregnancy rate

Pregnancy rate per OPU Given the large number of oocytes and embryos obtained (with no risk of OHSS) the clinical rate per OPU (fresh and thaw cycles combined) is more relevant to the patient.

Clinical use of agonist trigger opinion Primarily in the context of OHSS prevention. A major reason to use GnRH antagonists in ovarian stimulation: to keep the option of agonist trigger if needed.

RCT: Catch 22… A large body of observational data shows that agonist trigger completely prevents OHSS. Unethical to randomize high risk patients to hCG arm. No RCT, no formal recognition, no endorsement, no implementation…

If not RCT let’s consider mechanism The origin of OHSS is hyper-function of CL. No OHSS without CL. How to induce luteolysis? Surgical: “Bilateral partial oophorectomy in the management of severe OHSS. Amarin, HR 2003 Medical: Trigger with a GnRH agonist.

Prevention of ovarian hyperstimulation syndrome: Cochrane database Embryo freezing: insufficient evidence… Coasting: insufficient evidence… Albumin: clear benefit…

Further study Luteal LH secretion pattern post agonist trigger. Fine-tuning GnRH agonist dose, potency, route. Fine-tuning luteal support: keep estradiol high? Freeze all embryos to increase pregnancy rate, not to prevent OHSS…

Suggested protocol for the high responder Start stimulation with 150-225 IU rec FSH. Start antagonist on day 6 of stimulation. Consider adding 1 rec LH (75 IU) daily. Ignore E2 levels! No need to step down! Give all growing follicles full FSH support! Trigger with 0.2 mg triptorelin. Start luteal support on day of OPU. Use vaginal E2 and P.

Agonist trigger to OHSS ICSI to male factor infertility is like ICSI to male factor infertility

Thank you